Oral pharmaceutical composition of teriparatide or abaloparatide

Abstract

The invention belongs to the field of biological medicine, and particularly relates to an oral pharmaceutical composition of teriparatide or abaloparatide. The pharmaceutical composition is prepared from teriparatide or abaloparatide and a pharmaceutical composition for promoting small intestine absorption, wherein the pharmaceutical composition for promoting small intestine absorption consists of lauryl sodium sulfate, chitosan and sodium citrate. According to the pharmaceutical composition for promoting small intestine absorption, a composite adjuvant is prepared, and after the composite adjuvant is combined with the teriparatide or abaloparatide, the absorption of the effective component in the small intestine can be improved.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to an oral pharmaceutical composition of teriparatide or abalolotide. Background technique [0002] Teriparatide is a synthetic polypeptide hormone, which is a 1-34 amino acid fragment of human parathyroid hormone PTH, which is the biologically active N-terminal region of endogenous parathyroid hormone PTH containing 84 amino acids. The immunological and biological properties of this drug are identical to those of endogenous parathyroid hormone PTH and bovine parathyroid hormone PTH (bPTH). Teriparatide stimulates bone formation and resorption, reduces the incidence of fractures in postmenopausal women, and, depending on the mode of administration, increases or decreases bone mineral density. Continuous infusions result in sustained increases in PTH concentrations and thus produce greater bone resorption than daily injections that result in only transient increases ...

AI Technical Summary

Problems solved by technology

[0004] Neither teriparatide nor abalotropide can be taken orally, which leads to poor patient compliance. Th

Images